(Beijing Comprehensive News) The Ministry of National Security of China issued a document to encourage the whole society to mobilize the anti -spy work and commend and reward the reporting spy behavior.After the official WeChat of the Ministry of National Security was launched on Monday (July 31), the first article was released on Tuesday (August 1) and made the above appeal.The article wrote that the current situation of China's anti -espionage struggle is severe and complicated. The national security organs must conscientiously implement the anti -spy law, build anti -spy national security people's defense line, and form a normal mechanism for the people to participate in the anti -spy work.The article elaborates a series of provisions after the revision of the anti -spy law, and the anti -spy spy -spy law is explained from the five aspects of legislative purpose, work principles, legal obligations, rights guarantee and working system.The law put forward requirements, including confidentiality for reporters, commending and rewarding the reporting spy behavior.The Anti -Spy Law was revised and approved by the 14th China People's Congress Standing Committee in April this year, and it was formally implemented since July 1.After the revision, the anti -espionage law expanded the spy behavior from national secrets and intelligence to "other documents, data, data, and items that are related to national security and interests, but the law did not specifically explain the" related national security and interests ".After the revision of the Anti -Spy Law, it caused concerns about foreign companies in China, and the company's normal business activities may be punished.In this regard, the Ministry of Commerce of China had called on the China Foreign Chamber of Commerce and Corporate representatives on July 21 to explain the new version of the Anti -Spy Law to stabilize the confidence in China in China.According to Reuters, in recent years, dozens of Chinese and foreigners have been arrested and detained for suspected spy, including a senior executive of Japanese pharmaceuticals Anstela Pharmaceutical Company.